Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.35 |
| ▸ | GCKR | Q14397 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20085931 | 0.85 | MAPT (0.46) | DHFRHSD11B1MEN1KMT2AMAPT | |
| SCHEMBL22601459 | 0.84 | MAPT (0.50) | DHFRHSD11B1MEN1KMT2AMAPT | |
| SCHEMBL16256660 | 0.83 | MAPT (0.53) | DHFRHSD11B1MEN1KMT2AMAPT | |
| SCHEMBL20224118 | 0.81 | GAA (0.50) | DHFRHSD11B1MAPTPPARDPPARA | |
| SCHEMBL20224117 | 0.81 | HRH3 (0.50) | DHFRHSD11B1MAPT | |
| SCHEMBL2447732 | 0.80 | DPP4 (0.39) | DHFRHSD11B1MEN1KMT2AMAPT | |
| SCHEMBL14008911 | 0.80 | POLB (0.55) | HSD11B1MEN1KMT2AMAPTPOLB | |
| SCHEMBL12145921 | 0.80 | CHRNB2 (0.58) | CHRNB2CHRNA4HTR3A | |
| SCHEMBL24422281 | 0.80 | MAPT (0.38) | HSD11B1MEN1KMT2AMAPTGPR119 | |
| SCHEMBL30477815 | 0.80 | GCK (0.45) | DHFRHSD11B1KMT2AMAPTCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | AMGEN INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20220195059-A1 | Rank Pathway Inhibitors in Combination with CDK Inhibitors | Instituto de Medicina Molecular João Lobo Antunes (PT) | 2022-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151432-A1 | KIF18A INHIBITORS FOR TREATMENT OF NEOPLASTIC DISEASES | KIF18A, KIF18B, KIF20A | DHFR 1500/4885HSD11B1 3042/4885MEN1 1697/4885 |
| US-20220195059-A1 | Rank Pathway Inhibitors in Combination with CDK Inhibitors | CDK8, CDK3, CDK6 | DHFR 632/4885HSD11B1 2607/4885MEN1 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.